About this Journal Submit a Manuscript Table of Contents
Journal of Biomedicine and Biotechnology
Volume 2011 (2011), Article ID 439397, 11 pages
http://dx.doi.org/10.1155/2011/439397
Review Article

The Role of Molecular Imaging in the Diagnosis and Management of Neuropsychiatric Disorders

1Institute of Nuclear Energy Research, Lungtan, Taoyuan 325, Taiwan
2Institute of Pharmacology, School of Medicine, National Yang-Ming University, Taipei 112, Taiwan
3Department of Chemistry, Chung Yuan Christian University, Chung-Li 320, Taiwan

Received 27 December 2010; Accepted 15 February 2011

Academic Editor: David J. Yang

Copyright © 2011 Lie-Hang Shen et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. M. Fumita and R. B. Innis, “In vivo molecular imaging: ligand development and research applications,” in Neuropsychopharmacology: The Fifth Generation of Progress, pp. 411–425, 2000.
  2. W. D. Heiss and K. Herholz, “Brain receptor imaging,” Journal of Nuclear Medicine, vol. 47, no. 2, pp. 302–312, 2006. View at Scopus
  3. N. Pavese, L. Kiferle, and P. Piccini, “Neuroprotection and imaging studies in Parkinson's disease,” Parkinsonism and Related Disorders, vol. 15, no. 4, pp. S33–S37, 2010. View at Publisher · View at Google Scholar · View at Scopus
  4. D. J. Gelb, E. Oliver, and S. Gilman, “Diagnostic criteria for Parkinson disease,” Archives of Neurology, vol. 56, no. 1, pp. 33–39, 1999. View at Publisher · View at Google Scholar · View at Scopus
  5. E. Tolosa, G. Wenning, and W. Poewe, “The diagnosis of Parkinson's disease,” Lancet Neurology, vol. 5, no. 1, pp. 75–86, 2006. View at Publisher · View at Google Scholar · View at Scopus
  6. A. J. Hughes, S. E. Daniel, S. Blankson, and A. J. Lees, “A clinicopathologic study of 100 cases of Parkinson's disease,” Archives of Neurology, vol. 50, no. 2, pp. 140–148, 1993. View at Scopus
  7. A. H. Rajput, B. Rozdilsky, and A. Rajput, “Accuracy of clinical diagnosis in Parkinsonism—a prospective study,” Canadian Journal of Neurological Sciences, vol. 18, no. 3, pp. 275–278, 1991. View at Scopus
  8. C. Sioka, A. Fotopoulos, and A. P. Kyritsis, “Recent advances in PET imaging for evaluation of Parkinson's disease,” European Journal of Nuclear Medicine and Molecular Imaging, vol. 37, pp. 1594–1603, 2010. View at Publisher · View at Google Scholar · View at Scopus
  9. D. J. Brooks, K. A. Frey, K. L. Marek et al., “Assessment of neuroimaging techniques as biomarkers of the progression of Parkinson's disease,” Experimental Neurology, vol. 184, no. 1, pp. S68–S79, 2003. View at Publisher · View at Google Scholar · View at Scopus
  10. N. Pavese and D. J. Brooks, “Imaging neurodegeneration in Parkinson's disease,” Biochimica et Biophysica Acta, vol. 1792, no. 7, pp. 722–729, 2009. View at Publisher · View at Google Scholar · View at Scopus
  11. M. J. Ribeiro, M. Vidailhet, C. Loc'h et al., “Dopaminergic function and dopamine transporter binding assessed with positron emission tomography in Parkinson disease,” Archives of Neurology, vol. 59, no. 4, pp. 580–586, 2002. View at Scopus
  12. S. K. Meegalla, K. Plössl, M. P. Kung et al., “Synthesis and characterization of technetium-99m-labeled tropanes as dopamine transporter-imaging agents,” Journal of Medicinal Chemistry, vol. 40, no. 1, pp. 9–17, 1997. View at Publisher · View at Google Scholar · View at Scopus
  13. P. D. Mozley, J. S. Schneider, P. D. Acton et al., “Binding of [99mTc]TRODAT-1 to dopamine transporters in patients with Parkinson's disease and in healthy volunteers,” Journal of Nuclear Medicine, vol. 41, no. 4, pp. 584–589, 2000. View at Scopus
  14. W. S. Huang, Y. H. Chiang, J. C. Lin, Y. H. Chou, C. Y. Cheng, and R. S. Liu, “Crossover study of 99mTc-TRODAT-1 SPECT and 18F-FDOPA PET in Parkinson's disease patients,” Journal of Nuclear Medicine, vol. 44, no. 7, pp. 999–1005, 2003. View at Scopus
  15. Y. H. Weng, T. C. Yen, M. C. Chen et al., “Sensitivity and specificity of 99mTc-TRODAT-1 SPECT imaging in differentiating patients with idiopathic Parkinson's disease from healthy subjects,” Journal of Nuclear Medicine, vol. 45, no. 3, pp. 393–401, 2004. View at Scopus
  16. E. Nurmi, H. M. Ruottinen, J. Bergman et al., “Rate of progression in Parkinson's disease: a 6-[18F]fluoro-L-dopa PET study,” Movement Disorders, vol. 16, no. 4, pp. 608–615, 2001. View at Publisher · View at Google Scholar · View at Scopus
  17. L. Farde, S. Pauli, H. Hall et al., “Stereoselective binding of 11C-raclopride in living human brain - A search for extrastriatal central D2-dopamine receptors by PET,” Psychopharmacology, vol. 94, no. 4, pp. 471–478, 1988. View at Scopus
  18. K. Y. Tzen, C. S. Lu, T. C. Yen, S. P. Wey, and G. Ting, “Differential diagnosis of Parkinson's disease and vascular parkinsonism by [99mTc]-TRODAT-1,” Journal of Nuclear Medicine, vol. 42, no. 3, pp. 408–413, 2001. View at Scopus
  19. W. Koch, C. Hamann, P. E. Radau, and K. Tatsch, “Does combined imaging of the pre- and postsynaptic dopaminergic system increase the diagnostic accuracy in the differential diagnosis of parkinsonism?” European Journal of Nuclear Medicine and Molecular Imaging, vol. 34, no. 8, pp. 1265–1273, 2007. View at Publisher · View at Google Scholar · View at Scopus
  20. M. Plotkin, H. Amthauer, S. Klaffke et al., “Combined 123I-FP-CIT and I-IBZM SPECT for the diagnosis of parkinsonian syndromes: study on 72 patients,” Journal of Neural Transmission, vol. 112, no. 5, pp. 677–692, 2005. View at Publisher · View at Google Scholar · View at Scopus
  21. R. Pahwa and K. E. Lyons, “Early diagnosis of Parkinson's disease: recommendations from diagnostic clinical guidelines,” The American Journal of Managed Care, vol. 16, pp. S94–99, 2010. View at Scopus
  22. Y. H. Weng, Y. H. W. Chou, W. S. Wu et al., “PINK1 mutation in Taiwanese early-onset parkinsonismml: clinical, genetic, and dopamine transporter studies,” Journal of Neurology, vol. 254, no. 10, pp. 1347–1355, 2007. View at Publisher · View at Google Scholar · View at Scopus
  23. T. C. Yen, K. Y. Tzen, M. C. Chen et al., “Dopamine transporter concentration is reduced in asymptomatic Machado-Joseph disease gene carriers,” Journal of Nuclear Medicine, vol. 43, no. 2, pp. 153–159, 2002. View at Scopus
  24. A. Antonini, “Imaging for early differential diagnosis of parkinsonism,” The Lancet Neurology, vol. 9, no. 2, pp. 130–131, 2010. View at Publisher · View at Google Scholar · View at Scopus
  25. C. R. Freed, P. E. Greene, R. E. Breeze et al., “Transplantation of embryonic dopamine neurons for severe Parkinson's disease,” New England Journal of Medicine, vol. 344, no. 10, pp. 710–719, 2001. View at Publisher · View at Google Scholar · View at Scopus
  26. Y. Ma, C. Tang, T. Chaly et al., “Dopamine cell implantation in Parkinson's disease: long-term clinical and 18F-FDOPA PET outcomes,” Journal of Nuclear Medicine, vol. 51, no. 1, pp. 7–15, 2010. View at Publisher · View at Google Scholar · View at Scopus
  27. A. E. Lang, S. Gill, N. K. Patel et al., “Randomized controlled trial of intraputamenal glial cell line-derived neurotrophic factor infusion in Parkinson disease,” Annals of Neurology, vol. 59, no. 3, pp. 459–466, 2006. View at Publisher · View at Google Scholar · View at Scopus
  28. A. L. Berry and T. Foltynie, “Gene therapy: a viable therapeutic strategy for Parkinson's disease?” Journal of Neurology, vol. 258, pp. 179–188, 2010.
  29. W. J. Marks Jr., J. L. Ostrem, L. Verhagen et al., “Safety and tolerability of intraputaminal delivery of CERE-120 (adeno-associated virus serotype 2-neurturin) to patients with idiopathic Parkinson's disease: an open-label, phase I trial,” The Lancet Neurology, vol. 7, no. 5, pp. 375–376, 2008. View at Publisher · View at Google Scholar · View at Scopus
  30. M. G. Kaplitt, A. Feigin, C. Tang et al., “Safety and tolerability of gene therapy with an adeno-associated virus (AAV) borne GAD gene for Parkinson's disease: an open label, phase I trial,” Lancet, vol. 369, no. 9579, pp. 2097–2105, 2007. View at Publisher · View at Google Scholar · View at Scopus
  31. J. L. Eberling, W. J. Jagust, C. W. Christine et al., “Results from a phase I safety trial of hAADC gene therapy for Parkinson disease,” Neurology, vol. 70, no. 21, pp. 1980–1983, 2008. View at Publisher · View at Google Scholar · View at Scopus
  32. L. Leriche, T. Björklund, N. Breysse et al., “Positron emission tomography imaging demonstrates correlation between behavioral recovery and correction of dopamine neurotransmission after gene therapy,” Journal of Neuroscience, vol. 29, no. 5, pp. 1544–1553, 2009. View at Publisher · View at Google Scholar · View at Scopus
  33. S. I. Muramatsu, K. I. Fujimoto, S. Kato et al., “A phase I study of aromatic L-amino acid decarboxylase gene therapy for Parkinson's disease,” Molecular Therapy, vol. 18, pp. 1731–1735, 2010. View at Publisher · View at Google Scholar · View at Scopus
  34. K. Blennow, M. J. de Leon, and H. Zetterberg, “Alzheimer’s disease,” Lancet, vol. 368, pp. 387–403, 2006.
  35. R. Brookmeyer, E. Johnson, K. Ziegler-Graham, and H. M. Arrighi, “Forecasting the global burden of Alzheimer's disease,” Alzheimer's and Dementia, vol. 3, no. 3, pp. 186–191, 2007. View at Publisher · View at Google Scholar · View at Scopus
  36. A. Kadir and A. Nordberg, “Target-specific PET probes for neurodegenerative disorders related to dementia,” Journal of Nuclear Medicine, vol. 51, no. 9, pp. 1418–1430, 2010. View at Publisher · View at Google Scholar
  37. M. P. Mattson, “Pathways towards and away from Alzheimer's disease,” Nature, vol. 430, no. 7000, pp. 631–639, 2004. View at Publisher · View at Google Scholar · View at Scopus
  38. W. Jagust, “Positron emission tomography and magnetic resonance imaging in the diagnosis and prediction of dementia,” Alzheimer's and Dementia, vol. 2, no. 1, pp. 36–42, 2006. View at Publisher · View at Google Scholar · View at Scopus
  39. D. H. S. Silverman, G. W. Small, and M. E. Phelps, “Clinical value of neuroimaging in the diagnosis of dementia. Sensitivity and specificity of regional cerebral metabolic and other parameters for early identification of Alzheimer's disease,” Clinical Positron Imaging, vol. 2, no. 3, pp. 119–130, 1999. View at Publisher · View at Google Scholar · View at Scopus
  40. H. Engler, A. Forsberg, O. Almkvist et al., “Two-year follow-up of amyloid deposition in patients with Alzheimer's disease,” Brain, vol. 129, no. 11, pp. 2856–2866, 2006. View at Publisher · View at Google Scholar · View at Scopus
  41. A. Nordberg, “PET imaging of amyloid in Alzheimer's disease,” Lancet Neurology, vol. 3, no. 9, pp. 519–527, 2004. View at Publisher · View at Google Scholar · View at Scopus
  42. A. Nordberg, “Amyloid imaging in Alzheimer's disease,” Neuropsychologia, vol. 46, no. 6, pp. 1636–1641, 2008. View at Publisher · View at Google Scholar · View at Scopus
  43. A. Nordberg, “Amyloid plaque imaging in vivo: current achievement and future prospects,” European Journal of Nuclear Medicine and Molecular Imaging, vol. 35, no. 1, pp. S46–S50, 2008. View at Publisher · View at Google Scholar · View at Scopus
  44. V. Valotassiou, S. Archimandritis, N. Sifakis, J. Papatriantafyllou, and P. Georgoulias, “Alzheimer's disease: SPECT and PET tracers for beta-amyloid imaging,” Current Alzheimer Research, vol. 7, no. 6, pp. 477–486, 2010. View at Publisher · View at Google Scholar
  45. K. Shoghi-Jadid, G. W. Small, E. D. Agdeppa et al., “Localization of neurofibrillary tangles and beta-amyloid plaques in the brains of living patients with alzheimer disease,” American Journal of Geriatric Psychiatry, vol. 10, no. 1, pp. 24–35, 2002. View at Publisher · View at Google Scholar · View at Scopus
  46. C. A. Mathis, B. J. Bacskai, S. T. Kajdasz et al., “A lipophilic thioflavin-T derivative for positron emission tomography (PET) imaging of amyloid in brain,” Bioorganic and Medicinal Chemistry Letters, vol. 12, no. 3, pp. 295–298, 2002. View at Publisher · View at Google Scholar · View at Scopus
  47. W. E. Klunk, H. Engler, A. Nordberg et al., “Imaging Brain Amyloid in Alzheimer's Disease with Pittsburgh Compound-B,” Annals of Neurology, vol. 55, no. 3, pp. 306–319, 2004. View at Publisher · View at Google Scholar · View at Scopus
  48. R. C. Petersen, G. E. Smith, S. C. Waring, R. J. Ivnik, E. G. Tangalos, and E. Kokmen, “Mild cognitive impairment: clinical characterization and outcome,” Archives of Neurology, vol. 56, no. 3, pp. 303–308, 1999. View at Scopus
  49. S. M. Landau, D. Harvey, C. M. Madison, et al., “The Alzheimer's Disease Neuroimaging Initiative. Associations between cognitive, functional, and FDG-PET measures of decline in AD and MCI,” Neurobiology of Aging. In press.
  50. A. Forsberg, H. Engler, O. Almkvist et al., “PET imaging of amyloid deposition in patients with mild cognitive impairment,” Neurobiology of Aging, vol. 29, no. 10, pp. 1456–1465, 2008. View at Publisher · View at Google Scholar · View at Scopus
  51. D. F. Wong, P. B. Rosenberg, Y. Zhou et al., “In vivo imaging of amyloid deposition in Alzheimer disease using the radioligand 18F-AV-45 (flobetapir F 18),” Journal of Nuclear Medicine, vol. 51, no. 6, pp. 913–920, 2010. View at Scopus
  52. N. P. L. G. Verhoeff, A. A. Wilson, S. Takeshita et al., “In-vivo imaging of Alzheimer disease β-amyloid with [11C]SB-13 PET,” American Journal of Geriatric Psychiatry, vol. 12, no. 6, pp. 584–595, 2004. View at Publisher · View at Google Scholar · View at Scopus
  53. N. Tolboom, W. M. Van Der Flier, J. Boverhoff et al., “Molecular imaging in the diagnosis of Alzheimer's disease: visual assessment of [11C]PIB and [18F]FDDNP PET images,” Journal of Neurology, Neurosurgery and Psychiatry, vol. 81, no. 8, pp. 882–884, 2010. View at Publisher · View at Google Scholar
  54. R. Vandenberghe, K. Van Laere, A. Ivanoiu, et al., “18F-flutemetamol amyloid imaging in Alzheimer disease and mild cognitive impairment: a phase 2 trial,” Annals of Neurology, vol. 68, pp. 319–329, 2010.
  55. J. Hardy and D. J. Selkoe, “The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics,” Science, vol. 297, no. 5580, pp. 353–356, 2002. View at Publisher · View at Google Scholar · View at Scopus
  56. A. Kadir, N. Andreasen, O. Almkvist et al., “Effect of phenserine treatment on brain functional activity and amyloid in Alzheimer's disease,” Annals of Neurology, vol. 63, no. 5, pp. 621–631, 2008. View at Publisher · View at Google Scholar · View at Scopus
  57. D. E. Kuhl, S. Minoshima, K. A. Frey, N. L. Foster, M. R. Kilbourn, and R. A. Koeppe, “Limited donepezil inhibition of acetylcholinesterase measured with positron emission tomography in living Alzheimer cerebral cortex,” Annals of Neurology, vol. 48, no. 3, pp. 391–395, 2000. View at Publisher · View at Google Scholar · View at Scopus
  58. R. V. Parsey, “Serotonin receptor imaging: clinically useful?” Journal of Nuclear Medicine, vol. 51, no. 10, pp. 1495–1498, 2010. View at Publisher · View at Google Scholar
  59. S. Sobczak, A. Honig, M. A. van Duinen, and W. J. Riedel, “Serotonergic dysregulation in bipolar disorders: a literature review of serotonergic challenge studies,” Bipolar Disorders, vol. 4, no. 6, pp. 347–356, 2002. View at Publisher · View at Google Scholar · View at Scopus
  60. A. Neumeister, E. Bain, A. C. Nugent et al., “Reduced serotonin type 1 receptor binding in panic disorder,” Journal of Neuroscience, vol. 24, no. 3, pp. 589–591, 2004. View at Publisher · View at Google Scholar · View at Scopus
  61. W. C. Drevets, E. Frank, J. C. Price et al., “PET imaging of serotonin 1A receptor binding in depression,” Biological Psychiatry, vol. 46, no. 10, pp. 1375–1387, 1999. View at Publisher · View at Google Scholar · View at Scopus
  62. W. C. Drevets, E. Frank, J. C. Price, D. J. Kupfer, P. J. Greer, and C. Mathis, “Serotonin type-1A receptor imaging in depression,” Nuclear Medicine and Biology, vol. 27, no. 5, pp. 499–507, 2000. View at Publisher · View at Google Scholar · View at Scopus
  63. J. Blin, G. Sette, M. Fiorelli et al., “A method for the in vivo investigation in the serotonergic 5-HT2 receptors in the human cerebral cortex using positron emission tomography and 18F-labeled setoperone,” Journal of Neurochemistry, vol. 54, no. 5, pp. 1744–1754, 1990. View at Scopus
  64. J. Blin, J. C. Baron, B. Dubois et al., “Loss of brain 5-HT2 receptors in Alzheimer's disease. In vivo assessment with positron emission tomography and [18F]setoperone,” Brain, vol. 116, no. 3, pp. 497–510, 1993. View at Scopus
  65. E. T. C. Ngan, L. N. Yatham, T. J. Ruth, and P. F. Liddle, “Decreased serotonin 2A receptor densities in neuroleptic-naive patients with schizophrenia: a pet study using [18F]setoperone,” American Journal of Psychiatry, vol. 157, no. 6, pp. 1016–1018, 2000. View at Publisher · View at Google Scholar · View at Scopus
  66. W. A. Wolf and D. M. Kuhn, “Modulation of serotonin release: interactions between the serotonin transporter and autoreceptors,” Annals of the New York Academy of Sciences, vol. 604, pp. 505–513, 1990. View at Publisher · View at Google Scholar · View at Scopus
  67. M. Suehiro, U. Scheffel, H. T. Ravert, R. F. Dannals, and H. N. Wagner, “[11C](+)McN5652 as a radiotracer for imaging serotonin uptake sites with PET,” Life Sciences, vol. 53, no. 11, pp. 883–892, 1993. View at Scopus
  68. S. Hesse, H. Barthel, J. Schwarz, O. Sabri, and U. Müller, “Advances in in vivo imaging of serotonergic neurons in neuropsychiatric disorders,” Neuroscience and Biobehavioral Reviews, vol. 28, no. 6, pp. 547–563, 2004. View at Publisher · View at Google Scholar · View at Scopus
  69. J. H. Meyer, “Imaging the serotonin transporter during major depressive disorder and antidepressant treatment,” Journal of Psychiatry and Neuroscience, vol. 32, no. 2, pp. 86–102, 2007. View at Scopus
  70. K. J. Lin, C. Y. Liu, S. P. Wey et al., “Brain SPECT imaging and whole-body biodistribution with [123I]ADAM—a serotonin transporter radiotracer in healthy human subjects,” Nuclear Medicine and Biology, vol. 33, no. 2, pp. 193–202, 2006. View at Publisher · View at Google Scholar · View at Scopus
  71. Z. Bhagwagar, N. Murthy, S. Selvaraj et al., “5-HTT binding in recovered depressed patients and healthy volunteers: a positron emission tomography study with [11C]DASB,” American Journal of Psychiatry, vol. 164, no. 12, pp. 1858–1865, 2007. View at Publisher · View at Google Scholar · View at Scopus
  72. R. V. Parsey, R. S. Hastings, M. A. Oquendo et al., “Lower serotonin transporter binding potential in the human brain during major depressive episodes,” American Journal of Psychiatry, vol. 163, no. 1, pp. 52–58, 2006. View at Publisher · View at Google Scholar · View at Scopus
  73. J. H. Meyer, A. A. Wilson, N. Ginovart et al., “Occupancy of serotonin transporters by paroxetine and citalopram during treatment of depression: a [11C]DASB PET imaging study,” American Journal of Psychiatry, vol. 158, no. 11, pp. 1843–1849, 2001. View at Publisher · View at Google Scholar · View at Scopus
  74. J. H. Meyer, S. Houle, S. Sagrati et al., “Brain serotonin transporter binding potential measured with [11C]DASB positron emission tomography: effects of major depressive episodes and severity of dysfunctional attitudes,” Archives of General Psychiatry, vol. 61, no. 12, pp. 1271–1279, 2004. View at Publisher · View at Google Scholar · View at Scopus
  75. A. B. Newberg, J. D. Amsterdam, N. Wintering et al., “123I-ADAM binding to serotonin transporters in patients with major depression and healthy controls: a preliminary study,” Journal of Nuclear Medicine, vol. 46, no. 6, pp. 973–977, 2005. View at Scopus
  76. N. Herold, K. Uebelhack, L. Franke et al., “Imaging of serotonin transporters and its blockade by citalopram in patients with major depression using a novel SPECT ligand [123I]-ADAM,” Journal of Neural Transmission, vol. 113, no. 5, pp. 659–670, 2006. View at Publisher · View at Google Scholar · View at Scopus
  77. S. Sobczak, A. Honig, M. A. van Duinen, and W. J. Riedel, “Serotonergic dysregulation in bipolar disorders: a literature review of serotonergic challenge studies,” Bipolar Disorders, vol. 4, no. 6, pp. 347–356, 2002. View at Publisher · View at Google Scholar · View at Scopus
  78. G. Murray and S. L. Johnson, “The clinical significance of creativity in bipolar disorder,” Clinical Psychology Review, vol. 30, pp. 721–732, 2010. View at Publisher · View at Google Scholar · View at Scopus
  79. Y. H. Chou, S. J. Wang, C. L. Lin, W. C. Mao, S. M. Lee, and M. H. Liao, “Decreased brain serotonin transporter binding in the euthymic state of bipolar I but not bipolar II disorder: a SPECT study,” Bipolar Disorders, vol. 12, no. 3, pp. 312–318, 2010. View at Publisher · View at Google Scholar · View at Scopus
  80. T. T. Chang, T. L. Yeh, N. T. Chiu et al., “Higher striatal dopamine transporters in euthymic patients with bipolar disorder: a SPECT study with [99mTc] TRODAT-1,” Bipolar Disorders, vol. 12, no. 1, pp. 102–106, 2010. View at Publisher · View at Google Scholar · View at Scopus
  81. Y. K. Yang, W. J. Yao, T. L. Yeh, I. H. Lee, K. C. Chen, and R. B. Lu, “Association between serotonin transporter availability and hostility scores in healthy volunteers—a single photon emission computed tomography study with [123I] ADAM,” Psychiatry Research, vol. 154, no. 3, pp. 281–284, 2007. View at Publisher · View at Google Scholar
  82. C. Hiemke, “Therapeutic drug monitoring in neuropsychopharmacology: does it hold its promises?” European Archives of Psychiatry and Clinical Neuroscience, vol. 258, no. 1, supplement, pp. 21–27, 2008. View at Publisher · View at Google Scholar · View at Scopus
  83. M. Sekine, R. Arakawa, H. Ito et al., “Norepinephrine transporter occupancy by antidepressant in human brain using positron emission tomography with (S,S)-[18F]FMeNER-D,” Psychopharmacology, vol. 210, pp. 331–336, 2010. View at Publisher · View at Google Scholar · View at Scopus
  84. Y. S. Ding, T. Singhal, B. Planeta-Wilson et al., “PET imaging of the effects of age and cocaine on the norepinephrine transporter in the human brain using (S,S)-[11C]O-methylreboxetine and HRRT,” Synapse, vol. 64, no. 1, pp. 30–38, 2010. View at Publisher · View at Google Scholar · View at Scopus
  85. M. Árgyelán, Z. Szabó, B. Kanyó et al., “Dopamine transporter availability in medication free and in bupropion treated depression: a 99mTc-TRODAT-1 SPECT study,” Journal of Affective Disorders, vol. 89, no. 1-3, pp. 115–123, 2005. View at Publisher · View at Google Scholar · View at Scopus
  86. L. Farde, F. A. Wiesel, C. Halldin, and G. Sedvall, “Central D2-dopamine receptor occupancy in schizophrenic patients treated with antipsychotic drugs,” Archives of General Psychiatry, vol. 45, no. 1, pp. 71–76, 1988. View at Scopus